Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-28
2010-10-19
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C536S007100
Reexamination Certificate
active
07816370
ABSTRACT:
The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect, such as schizophrenia or autism.
REFERENCES:
patent: 6518421 (2003-02-01), Li et al.
patent: 2003/0203929 (2003-10-01), Ghosh
patent: 198 21 954 (1998-11-01), None
patent: WO 98/22461 (1998-05-01), None
patent: WO 99/02514 (1999-01-01), None
patent: WO 99/07692 (1999-02-01), None
patent: WO 99/28324 (1999-06-01), None
patent: WO 99/62510 (1999-12-01), None
patent: WO 99/67252 (1999-12-01), None
patent: WO 00/49021 (2000-08-01), None
patent: WO 00/50423 (2000-08-01), None
patent: WO 00/66589 (2000-11-01), None
patent: WO 00/71521 (2000-11-01), None
patent: WO 01/70716 (2001-09-01), None
patent: WO 01/81341 (2001-11-01), None
patent: WO 01/92255 (2001-12-01), None
patent: WO 02/21712 (2002-03-01), None
patent: WO 02/41691 (2002-05-01), None
patent: WO 03/074053 (2003-09-01), None
patent: WO 03/096975 (2003-11-01), None
Nicole End et al , Synthetic Epothilone analogs with Modifications in the Northern Hemisphere and the Heterocyclic Side-Chain-Synthesis and Biological Evaluation, Fourth international Electronic Conference opn Synthetic Organic Chemistry (ECSOC-4).
Online Merck Mannuals acceesed on Oct. 26, 2009.
Buitelaar et al. (European Child and Adolescent psychiatri 9; I/85-97, Steinkopff Verlag (2000)).
Posey et al. ( Exp Opin. Pharmacother. (2001) 2(4):587-600).
Nicolaou et al.; “Chemical Biology of Epothilones;”Angewandte Chemie International Edition; vol. 37, No. 15; pp. 2014-2045; 1998; XP002131418.
N. C. Andreasen, “Scale for the Assessment of Negative Symptoms (SANS)”, Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa (1983) pp. 1-19.
Andreasen, Nancy C., “Schizophrenia: the fundamental questions,” Brain Research Interactive, Brain Research Reviews, vol. 31, 106-112 pp, (2000).
Frankle, W. Gordon et al., “The Synaptic Hypothesis of Schizophrenia,” Neuron, vol. 39, 205-216 pp, (2003).
Jamain, Stephane et al., “Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism,” Nature Genetics, vol. 34, 27-29 pp, (2003).
Andrieux, Annie et al., “The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders,” Genes & Development, vol. 16, 2350-2364 pp, (2002).
Kay, Stanley R. et al., “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,” Schizophrenia Bulletin, vol. 13, No. 2, 261-276 pp, (1987).
Lindenmayer, Jean-Pierre et al., “Five-Factor Model of Schizophrenia Initial Validation,” Journal of Nervous and Mental Disease, vol. 182, No. 11, 631-638 pp, (1994).
Mirnics, Karoly et al., “Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse,” Trends in Neurosciences, vol. 24, No. 8, 479-486 pp, (2001).
Oct. 27, 2009 Notice of Opposition issued in corresponding European Application No. 05702370.7-2123/1711230.
The Merck Manual of Diagnosis and Therapy, 17thEd., 1999, pp. 1563-1570.
Cader et al., “Reduced Brain Functional Reserve and Altered Functional Connectivity in Patients with Multiple Sclerosis,” Brain, vol. 129, 2006, pp. 527-537.
Erb et al., “Cytoarchitecture Cérébrale Dans La Schizophrénie,” Psychiatr Sci Hum Neurosci, vol. 7, 2009, pp. 23-30, with English Abstract.
Wu et al., “Changes of Functional Connectivity of the Motor Network in the Resting State in Parkinson's Disease,” Neuroscience Letters, vol. 460, 2009, pp. 6-10.
Andrieux Annie
Höfle Gerhard
Job Didier
Schweitzer Annie
Commissariat a l''Energie Atomique
Cornet Jean
Fetterolf Brandon J
Helmhaltz Zentrum Fur Infektions Forschung GmbH
Institut National de la Sante et de la Recherche Medicale
LandOfFree
Use of epothilones in the treatment of neuronal connectivity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of epothilones in the treatment of neuronal connectivity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of epothilones in the treatment of neuronal connectivity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220211